Life,
Год журнала:
2025,
Номер
15(1), С. 116 - 116
Опубликована: Янв. 16, 2025
Metabolic
dysfunction-associated
fatty
liver
disease
(MAFLD)
is
the
most
common
cause
of
chronic
worldwide,
with
a
multifactorial
etiology.
This
study
aims
to
evaluate
associations
between
various
sociodemographic
variables,
healthy
habits,
and
stress
risk
scale
values
for
MAFLD.
A
descriptive,
cross-sectional
was
conducted
on
16,708
Spanish
workers
assess
how
variables
(age,
gender,
socioeconomic
status),
habits
(smoking,
Mediterranean
diet
adherence,
physical
activity),
correlate
from
three
MAFLD
scales:
index
(FLI),
hepatic
steatosis
(HSI),
lipid
accumulation
product
(LAP).
All
analyzed
were
associated
scales.
Among
them,
showing
strongest
(represented
by
odds
ratio
values)
age
activity.
The
profile
an
individual
at
higher
elevated
male,
aged
50
or
older,
belonging
lower
levels
(manual
laborers),
smoker,
sedentary,
low
adherence
diet,
high
scores.
Journal of Hepatology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
The
liver
acts
as
a
central
metabolic
hub,
integrating
signals
from
the
gastrointestinal
tract
and
adipose
tissue
to
regulate
carbohydrate,
lipid,
amino
acid
metabolism.
Gut-derived
metabolites,
such
acetate
ethanol
non-esterified
fatty
acids
white
(WAT),
influence
hepatic
processes,
which
rely
on
mitochondrial
function
maintain
systemic
energy
balance.
Metabolic
dysregulation
obesity,
insulin
resistance,
type
2
diabetes
disrupt
these
pathways,
leading
dysfunction-associated
steatotic
disease
(MASLD)
steatohepatitis
(MASH).
This
review
explores
fluxes
within
gut-adipose
tissue-liver
axis,
focusing
pivotal
role
of
de
novo
lipogenesis
(DNL),
dietary
substrates
like
glucose
fructose,
changes
in
during
MASLD
progression.
It
highlights
contributions
resistance
impaired
dynamics
lipid
accumulation.
Further
understanding
how
interplay
between
substrate
flux
gastro-intestinal
integrates
with
intersects
structural
functional
alterations
mitochondria
will
be
important
identify
novel
therapeutic
targets
advance
treatment
MASH.
Liver International,
Год журнала:
2024,
Номер
44(3), С. 848 - 864
Опубликована: Янв. 23, 2024
Abstract
Background
and
Aims
Thyroid
axis
is
currently
under
investigation
as
a
therapeutic
target
in
metabolic
dysfunction‐associated
steatotic
liver
disease
(MASLD).
function
was
examined
herein
the
full
spectrum
of
disease.
Methods
Subjects
were
recruited
had
biopsies
two
Gastroenterology‐Hepatology
Clinics
(Greece
Australia)
one
Bariatric‐Metabolic
Surgery
Clinic
(Italy).
The
main
working
sample
n
=
677
subjects
with
MASLD
after
excluding
abnormal
free
thyroxine
levels.
Participants
classified
according
to
thyroid‐stimulating
hormone
(TSH)
standard
criteria:
Subclinical
hyperthyroidism
(<0.4
uIU/mL);
Euthyroidism
relatively
low
(0.4
<2.5
euthyroidism
high
(2.5–4.0
subclinical
hypothyroidism
(>4
uIU/mL).
Results
TSH
continuous
variable
positively
associated
significant
fibrosis
(
F
≥
2),
steatohepatitis
(MASH)
at‐risk
MASH.
2
(odds
ratio
[OR]
3.47,
95%
confident
interval
[CI]
[1.50,
8.05],
p
.02),
MASH
(OR
3.44,
CI
[1.48,
7.98]
.001)
3.88,
[1.76,
8.55],
.001),
before
controlling
for
adiposity,
central
obesity,
insulin
resistance.
When
leptin,
adiponectin,
or
growth
differentiation
factor‐15
moderators,
significance
lost.
Sex‐specific
analysis
revealed
strong
association
between
presence
among
women,
eliminated
only
when
adipokines/mitokines
adjusted
for.
Restricted
cubic
spline
associations
outcomes
‐values
<
.01)
inflection
points
being
2.49,
2.67
6.96.
Conclusions
These
observations
provide
support
studies
on
administration
thyroid
therapeutics
liver‐specific
receptor
agonists
across
continuum.
World Journal of Hepatology,
Год журнала:
2024,
Номер
16(6), С. 871 - 877
Опубликована: Июнь 19, 2024
Sarcopenia
and
metabolic
dysfunction
associated
steatotic
liver
disease
(MASLD)
are
closely
intertwined.
Sarcopenia,
traditionally
a
of
the
older
adult
chronic
population,
has
been
studied
as
one
pathophysiologic
conditions
at
play
in
development
MASLD.
They
share
similar
risk
factors
insulin
resistance
physical
inactivity.
Given
pathophysiology
along
liver-muscle
axis,
sarcopenia
factor
for
MASLD,
vice
versa.
Current
research
suggests
bidirectional
relationship.
chronicity
MASLD
inflammatory
disease,
it
can
break
down
muscle
mass
lead
to
sarcopenia,
while
promotes
intramuscular
lipid
accumulation
that
releases
cytokines
aggravate
inflammation
liver.
However,
longest
time,
lack
consensus
definition
made
difficult
study
their
relationship
outcomes.
A
recent
nomenclature
update
diagnosing
easier
researchers
identify
cohorts
study.
no
gold
standard
technique
measure
or
identified
yet.
Future
studies
needed
reach
reduce
diagnostic
variation.
With
shared
between
two
diseases,
future
may
also
potential
therapeutic
targets
axis
would
benefit
both
order
maximize
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(23), С. 12809 - 12809
Опубликована: Ноя. 28, 2024
From
a
detailed
review
of
90
experimental
and
clinical
metabolomic
investigations
obesity
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
we
have
developed
hallmarks
for
both
MASLD.
Obesity
studies
were
conducted
in
mice,
rats,
humans,
with
consensus
biomarker
groups
plasma/serum
being
essential
nonessential
amino
acids,
energy
metabolites,
gut
microbiota
acylcarnitines
lysophosphatidylcholines
(LPC),
which
formed
the
basis
six
obesity.
Additionally,
mice
rats
shared
elevated
cholesterol,
humans
fatty
VLDL/LDL,
bile
acids
phosphatidylcholines
(PC).
MASLD
had
been
performed
hamsters,
cows,
geese,
blunt
snout
breams,
zebrafish,
agreement
between
lay
foundation
five
Furthermore,
group
higher
LPC/PC
cholesteryl
esters,
acylcarnitines,
lysophosphatidylethanolamines/phosphatidylethanolamines
(LPE/PE),
triglycerides/diglycerides,
metabolites.
These
aid
understanding
role
played
by
development,
inform
mechanistic
into
underlying
pathogenesis,
are
critical
new
metabolite-inspired
therapies.
Metabolism,
Год журнала:
2024,
Номер
155, С. 155909 - 155909
Опубликована: Апрель 4, 2024
Krüppel-like
factor
10
(KLF10),
a
zinc
finger
transcription
factor,
plays
pivotal
role
in
modulating
TGF-β-mediated
cellular
processes
such
as
growth,
apoptosis,
and
differentiation.
Recent
studies
have
implicated
KLF10
regulating
lipid
metabolism
glucose
homeostasis.
This
study
aimed
to
elucidate
the
precise
of
hepatic
developing
metabolic
dysfunction-associated
steatohepatitis
(MASH)
diet-induced
obese
mice.
Seminars in Liver Disease,
Год журнала:
2024,
Номер
44(03), С. 273 - 286
Опубликована: Июль 11, 2024
The
new
nomenclature
of
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
emphasizes
a
positive
diagnosis
based
on
cardiometabolic
risk
factors.
This
definition
is
not
only
less
stigmatizing
but
also
allows
for
subclassification
and
stratification,
thereby
addressing
the
heterogeneity
what
was
historically
referred
to
as
nonalcoholic
fatty
disease.
within
this
spectrum
influenced
by
several
factors
which
include
are
limited
demographic/dietary
factors,
amount
alcohol
use
drinking
patterns,
status,
gut
microbiome,
genetic
predisposition
together
with
epigenetic
net
effect
dynamic
intricate
system-level
interaction
reflected
in
phenotypic
presentation
MASLD.
Therefore,
application
precision
medicine
scenario
aims
at
complex
phenotyping
consequent
individual
prediction,
development
individualized
preventive
strategies,
improvements
clinical
trial
designs.
In
review,
we
aim
highlight
importance
approaches
MASLD,
including
novel
biomarkers
disease,
its
subsequent
utilization
future
study
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(14), С. 4243 - 4243
Опубликована: Июль 20, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
and
polycystic
ovary
syndrome
(PCOS)
are
prevalent
conditions
that
have
been
correlated
with
infertility
through
overlapped
pathophysiological
mechanisms.
MASLD
is
associated
metabolic
considered
among
the
major
causes
of
chronic
disease,
while
PCOS,
which
characterized
by
ovulatory
dysfunction
hyperandrogenism,
one
leading
female
infertility.
The
links
between
PCOS
not
yet
fully
elucidated,
insulin
resistance,
hyperandrogenemia,
obesity,
dyslipidemia
being
key
pathways
contribute
to
lipid
accumulation,
inflammation,
fibrosis,
aggravating
dysfunction.
On
other
hand,
exacerbates
resistance
dysregulation
in
women
creating
a
vicious
cycle
progression.
Understanding
intricate
relationship
crucial
improving
clinical
management,
collaborative
efforts
different
medical
specialties
essential
optimize
fertility
health
outcomes
individuals
PCOS.
In
this
review,
we
summarize
complex
interplay
highlighting
importance
increasing
attention
prevention,
diagnosis,
treatment
both
entities.
npj Metabolic Health and Disease,
Год журнала:
2024,
Номер
2(1)
Опубликована: Авг. 2, 2024
Abstract
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
originates
from
a
homeostatic
imbalance
in
hepatic
lipid
metabolism.
Increased
fat
deposition
the
of
people
suffering
MASLD
predisposes
them
to
develop
further
metabolic
derangements,
including
diabetes
mellitus,
steatohepatitis
(MASH),
and
other
end-stage
diseases.
Unfortunately,
only
limited
pharmacological
therapies
exist
for
date.
Autophagy,
cellular
catabolic
process,
has
emerged
as
primary
mechanism
metabolism
mammalian
hepatocytes.
Furthermore,
preclinical
studies
with
autophagy
modulators
have
shown
promising
results
resolving
mitigating
its
progress
into
deleterious
pathologies.
In
this
review,
we
discuss
our
current
understanding
autophagy-mediated
metabolism,
therapeutic
modulation
treatment,
limitations
scope
clinical
translation.
